Downtrend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Apr 13 · inside the Ichimoku cloud · RSI 0 (oversold) · MACD above its signal · at its 52-week low
None of the 29 investors followed here reported a position in BIOAF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BIOAF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for BIOAF.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −50.0% | ||
| 2025 | 100.0 | 100.0 | 0.0 | 0.0 | -75.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +100.0% |
| 2024 | -8.5 | 62.8 | -48.6 | 11.1 | 0.0 | 0.0 | -97.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −97.9% |
| 2023 | -35.8 | -50.4 | 24.3 | -27.7 | -21.2 | -64.7 | 41.7 | -5.9 | 54.2 | -74.3 | 36.8 | 80.8 | −89.6% |
| 2022 | -3.2 | 1.7 | 0.5 | -13.7 | -3.4 | -23.6 | -21.3 | 18.7 | -2.4 | -1.8 | 3.8 | -63.7 | −78.7% |
| 2021 | 26.3 | -10.0 | 2.3 | -23.4 | -4.3 | 23.6 | -13.3 | -18.0 | 22.2 | -4.8 | -2.5 | -5.3 | −19.6% |
| 2020 | -23.4 | 3.9 | -28.9 | -5.1 | 1.5 | 90.4 | -10.4 | 52.0 | -6.5 | -14.5 | 6.8 | -0.4 | +20.0% |
| 2019 | 1.9 | -8.2 | -19.8 | -24.5 | 5.4 | -0.5 | -9.4 | 15.9 | -23.7 | -15.6 | 7.8 | 43.7 | −37.8% |
| 2018 | -2.6 | -11.0 | 35.5 | -25.9 | 26.5 | -34.4 | -17.3 | 4.1 | -21.5 | -7.3 | 6.5 | 25.1 | −39.6% |
| 2017 | -4.0 | -11.6 | -19.2 | 14.5 | -18.5 | 0.0 | -5.9 | 19.8 | 35.1 | -16.4 | -17.5 | 1.3 | −32.0% |
| 2016 | -7.8 | 4.4 | 23.1 | -4.1 | -2.1 | -6.3 | 14.8 | 16.3 | 4.5 | -16.2 | -11.0 | -11.3 | −3.8% |
| 2015 | -11.8 | 7.2 | 13.2 | 12.0 | -12.6 | -4.2 | -6.6 | -15.8 | 28.1 | -11.9 | 15.0 | -10.0 | −7.8% |
| 2014 | 33.6 | -22.2 | 19.5 | -17.8 | -8.0 | 10.6 | 8.4 | +12.7% |
No analyst coverage for this instrument.
Bioasis Technologies Inc. operates as a biopharmaceutical company. The company utilizes its proprietary xB3 platform to deliver therapeutics across the blood-brain barrier and treat central nervous system disorders in areas of high unmet medical need. Bioasis Technologies Inc. is based in New Haven, Connecticut.
No recent headlines.